← Back to Portfolio

SFJ XII (Nektar)

SFJ and Nektar are co-developing Bempeg (IL-2) in a phase 3 clinical study in head and neck cancer in a clinical co-development deal. The investment entity for this is SFJ XII. Necktar is listed on the Nasdaq with ticker NKTR.

LocationPleasanton, California
CEOBob DeBenedetto
Partner Kurt von Emster
Websitewww.sfjpharma.com